Clinical Trial

. 2021 May;22(3-4):287-299.

doi: 10.1080/21678421.2020.1822410. Epub 2020 Sep 24.

A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS

Jeremy M Shefner¹, Jinsy A Andrews², Angela Genge³, Carlayne Jackson⁴, Noah Lechtzin⁵, Timothy M Miller⁶, Bettina M Cockroft⁷, Lisa Meng⁷, Jenny Wei⁷, Andrew A Wolff⁷, Fady I Malik⁷, Cynthia Bodkin⁸, Benjamin R Brooks⁹, James Caress¹⁰, Annie Dionne¹¹, Dominic Fee¹², Stephen A Goutman¹³, Namita A Goyal¹⁴, Orla Hardiman¹⁵, Ghazala Hayat¹⁶, Terry Heiman-Patterson¹⁷, Daragh Heitzman¹⁸, Robert D Henderson¹⁹, Wendy Johnston²⁰, Chafic Karam²¹, Matthew C Kiernan²², Stephen J Kolb²³, Lawrence Korngut²⁴, Shafeeq Ladha²⁵, Genevieve Matte²⁶, Jesus S Mora²⁷, Merrilee Needham²⁸, Bjorn Oskarsson²⁹, Gary L Pattee³⁰, Erik P Pioro³¹, Michael Pulley³², Dianna Quan³³, Kourosh Rezania³⁴, Kerri L Schellenberg³⁵, David Schultz³⁶, Christen Shoesmith³⁷, Zachary Simmons³⁸, Jeffrey Statland³⁹, Shumaila Sultan⁴⁰, Andrea Swenson⁴¹, Leonard H Van Den Berg⁴², Tuan Vu⁴³, Steve Vucic⁴⁴, Michael Weiss⁴⁵, Ashley Whyte-Rayson⁴⁶, James Wymer⁴⁷, Lorne Zinman⁴⁸, Stacy A Rudnicki⁷

Affiliations

¹ Barrow Neurological Institute, Phoenix, AZ, USA.
² The Eleanor and Lou Gehrig ALS Center, The Neurological Institute, New York, NY, USA.
³ Montreal Neurological Institute, Montreal, QC, Canada.
⁴ University of Texas Health Science Center, San Antonio, TX, USA.
⁵ Johns Hopkins School of Medicine, Baltimore, MD, USA.
⁶ Washington University School of Medicine, St. Louis, MO, USA.
⁷ Cytokinetics, Inc, South San Francisco, CA, USA.
⁸ Indiana University School of Medicine, Indianapolis, IN, USA.
⁹ Atrium Health Neurosciences Institute-Carolinas Neuromuscular/ALS MDA Care Center, Charlotte, NC, USA.
¹⁰ Wake Forest Health Sciences, Winston-Salem, NC, USA.
¹¹ CHU de Québec, Université Laval, Quebec, Canada.
¹² Medical College of Wisconsin, Milwaukee, WI, USA.
¹³ University of Michigan, Ann Arbor, MI, USA.
¹⁴ The ALS & Neuromuscular Center, UCI Health, Orange, CA, USA.
¹⁵ Trinity College, Beaumont Hospital, Dublin, Ireland.
¹⁶ St. Louis University, St. Louis, MO, USA.
¹⁷ Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.
¹⁸ Texas Neurology, Dallas, TX, USA.
¹⁹ Royal Brisbane and Women's Hospital, Herston, Australia.
²⁰ University of Alberta, Edmonton, AB, Canada.
²¹ Oregon Health & Science University, Portland, OR, USA.
²² Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia.
²³ Wexner Medical Center, Ohio State University, Columbus, OH, USA.
²⁴ University of Calgary, Calgary, AB, Canada.
²⁵ St. Joseph's Hospital and Medical Center, Neurological Institute, AZ, USA Barrow Phoenix.
²⁶ Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.
²⁷ Hospital San Rafael, Madrid, Germany.
²⁸ Perron Institute, Department of Neurology, Fiona Stanley Hospital, The University of Notre Dame Australia, Murdoch University, Perth, Australia.
²⁹ Mayo Clinic Florida, Jacksonville, FL, USA.
³⁰ Neurology Associates, Lincoln, NE, USA.
³¹ Cleveland Clinic, Cleveland, OH, USA.
³² University of Florida, Jacksonville, FL, USA.
³³ University of Colorado Denver, Aurora, CO, USA.
³⁴ University of Chicago Medical Center, Chicago, IL, USA.
³⁵ University of Saskatchewan, Saskatoon, SK, Canada.
³⁶ Flinders Medical Centre, Bedford Park, Australia.
³⁷ London Health Sciences Centre, London, ON, Canada.
³⁸ Penn State Hershey Medical Center, Hershey, PA, USA.
³⁹ University of Kansas Medical Center, Kansas City, KS, USA.
⁴⁰ West Virginia University, Morgantown, WV, USA.
⁴¹ University of Iowa, Iowa City, IA, USA.
⁴² Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht, The Netherlands.
⁴³ University of South Florida, Tampa, FL, USA.
⁴⁴ Westmead Hospital, Sydney, Australia.
⁴⁵ University of Washington, Seattle, WA, USA.
⁴⁶ Duke University School of Medicine, Durham, NC, USA.
⁴⁷ University of Florida, Gainesville, FL, USA.
⁴⁸ ALS/Neuromuscular Clinic Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.

PMID: 32969758
PMCID: PMC8117790
DOI: 10.1080/21678421.2020.1822410

Clinical Trial

A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS

Jeremy M Shefner et al. Amyotroph Lateral Scler Frontotemporal Degener. 2021 May.

. 2021 May;22(3-4):287-299.

doi: 10.1080/21678421.2020.1822410. Epub 2020 Sep 24.

Authors

Affiliations

¹ Barrow Neurological Institute, Phoenix, AZ, USA.
² The Eleanor and Lou Gehrig ALS Center, The Neurological Institute, New York, NY, USA.
³ Montreal Neurological Institute, Montreal, QC, Canada.
⁴ University of Texas Health Science Center, San Antonio, TX, USA.
⁵ Johns Hopkins School of Medicine, Baltimore, MD, USA.
⁶ Washington University School of Medicine, St. Louis, MO, USA.
⁷ Cytokinetics, Inc, South San Francisco, CA, USA.
⁸ Indiana University School of Medicine, Indianapolis, IN, USA.
⁹ Atrium Health Neurosciences Institute-Carolinas Neuromuscular/ALS MDA Care Center, Charlotte, NC, USA.
¹⁰ Wake Forest Health Sciences, Winston-Salem, NC, USA.
¹¹ CHU de Québec, Université Laval, Quebec, Canada.
¹² Medical College of Wisconsin, Milwaukee, WI, USA.
¹³ University of Michigan, Ann Arbor, MI, USA.
¹⁴ The ALS & Neuromuscular Center, UCI Health, Orange, CA, USA.
¹⁵ Trinity College, Beaumont Hospital, Dublin, Ireland.
¹⁶ St. Louis University, St. Louis, MO, USA.
¹⁷ Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.
¹⁸ Texas Neurology, Dallas, TX, USA.
¹⁹ Royal Brisbane and Women's Hospital, Herston, Australia.
²⁰ University of Alberta, Edmonton, AB, Canada.
²¹ Oregon Health & Science University, Portland, OR, USA.
²² Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia.
²³ Wexner Medical Center, Ohio State University, Columbus, OH, USA.
²⁴ University of Calgary, Calgary, AB, Canada.
²⁵ St. Joseph's Hospital and Medical Center, Neurological Institute, AZ, USA Barrow Phoenix.
²⁶ Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.
²⁷ Hospital San Rafael, Madrid, Germany.
²⁸ Perron Institute, Department of Neurology, Fiona Stanley Hospital, The University of Notre Dame Australia, Murdoch University, Perth, Australia.
²⁹ Mayo Clinic Florida, Jacksonville, FL, USA.
³⁰ Neurology Associates, Lincoln, NE, USA.
³¹ Cleveland Clinic, Cleveland, OH, USA.
³² University of Florida, Jacksonville, FL, USA.
³³ University of Colorado Denver, Aurora, CO, USA.
³⁴ University of Chicago Medical Center, Chicago, IL, USA.
³⁵ University of Saskatchewan, Saskatoon, SK, Canada.
³⁶ Flinders Medical Centre, Bedford Park, Australia.
³⁷ London Health Sciences Centre, London, ON, Canada.
³⁸ Penn State Hershey Medical Center, Hershey, PA, USA.
³⁹ University of Kansas Medical Center, Kansas City, KS, USA.
⁴⁰ West Virginia University, Morgantown, WV, USA.
⁴¹ University of Iowa, Iowa City, IA, USA.
⁴² Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht, The Netherlands.
⁴³ University of South Florida, Tampa, FL, USA.
⁴⁴ Westmead Hospital, Sydney, Australia.
⁴⁵ University of Washington, Seattle, WA, USA.
⁴⁶ Duke University School of Medicine, Durham, NC, USA.
⁴⁷ University of Florida, Gainesville, FL, USA.
⁴⁸ ALS/Neuromuscular Clinic Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.

PMID: 32969758
PMCID: PMC8117790
DOI: 10.1080/21678421.2020.1822410

Abstract

To evaluate safety, dose response, and preliminary efficacy of reldesemtiv over 12 weeks in patients with amyotrophic lateral sclerosis (ALS). Methods: Patients (≤2 years since diagnosis) with slow upright vital capacity (SVC) of ≥60% were randomized 1:1:1:1 to reldesemtiv 150, 300, or 450 mg twice daily (bid) or placebo; active treatment was 12 weeks with 4-week follow-up. Primary endpoint was change in percent predicted SVC at 12 weeks; secondary measures included ALS Functional Rating Scale-Revised (ALSFRS-R) and muscle strength mega-score. Results: Patients (N = 458) were enrolled; 85% completed 12-week treatment. The primary analysis failed to reach statistical significance (p = 0.11); secondary endpoints showed no statistically significant effects (ALSFRS-R, p = 0.09; muscle strength mega-score, p = 0.31). Post hoc analyses pooling all active reldesemtiv-treated patients compared against placebo showed trends toward benefit in all endpoints (progression rate for SVC, ALSFRS-R, and muscle strength mega-score (nominal p values of 0.10, 0.01 and 0.20 respectively)). Reldesemtiv was well tolerated, with nausea and fatigue being the most common side effects. A dose-dependent decrease in estimated glomerular filtration rate was noted, and transaminase elevations were seen in approximately 5% of patients. Both hepatic and renal abnormalities trended toward resolution after study drug discontinuation. Conclusions: Although the primary efficacy analysis did not demonstrate statistical significance, there were trends favoring reldesemtiv for all three endpoints, with effect sizes generally regarded as clinically important. Tolerability was good; modest hepatic and renal abnormalities were reversible. The impact of reldesemtiv on patients with ALS should be assessed in a pivotal Phase 3 trial. (ClinicalTrials.gov Identifier: NCT03160898).

Keywords: Randomized clinical trial; amyotrophic lateral sclerosis; reldesemtiv.

PubMed Disclaimer

Conflict of interest statement

Declaration of interest

JMS received personal compensation from Avexis, Biogen, Brainstorm, Cytokinetics, Mitsubishi Tanabe Pharma America, Neurosense, Orphazyme, Otsuka, and Revalesio; and research support from Amylyx, Brainstorm, Cytokinetics, Medicinova, and Mitsubishi Tanabe Pharma America. JAA served as a consultant for ALS Pharma, Avexis, Biogen and Cytokinetics; is a former employee of Cytokinetics; and received research support from Biogen, Neuraltus, Orion, Roche, Novartis. AG served as a consultant for Alexion, AL-S Pharma, Biogen, Calico, and Cytokinetics. CJ has received grant support from Amylyx and Cytokinetics; served on the DSMB for Anelixis, Brainstorm, and Mallinckrodt; and served as a consultant for Cytokinetics, ITF Pharma, and Mitsubishi Tanabe Pharma America. NL is a consultant for Cytokinetics. TMM is a consultant for Cytokinetics and Disarm Therapeutics; has licensing agreements with C2N Diagnostics and Ionis Pharmaceuticals; and serves on the advisory board and receives research support from Biogen. CB served (uncompensated) on an advisory board for Argenx. BRB has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities from AB Science, Biogen, Biohaven, California ALS Research Summit, Cytokinetics, ITF Pharma, Mitsubishi Tanabe Pharma American, and for serving in an editorial capacity for American Journal of Managed Care; and has received research support from Acceleron, Alexion, Biogen, Biohaven, Boston Scientific, Center for Disease Control, Cytokinetics, ITF Pharma, Medicinova, Mitsubishi Tanabe Pharma America, Neuraltus, Orion, and Santhera. DF has served on an advisory board for Biogen Scientific. OH has received consulting fees from Novartis; research funding from Biogen, Cytokinetics, Ionis and Merck; and is Editor-in-Chief of Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. GH served on speaker’s bureau and as a consultant for Alexion, CSL Behring, KabaFusion, and Mitsubishi Tanabe Pharma. TH-P has received consulting fees from Amylyx, Cytokinetics, ITF Pharma and Mitsubishi Tanabe Pharma. RDH served on SMA advisory board for Biogen and Pompe advisory board (Sanofi). WJ received honoraria from Mitsubishi Tanabe Pharma Canada advisory board; and served on clinical trials for Alexion Pharmaceuticals, ALS-Pharma SA, Biogen, Cytokinetics, Mallinckrodt, Mitsubishi Tanabe Pharma Development America, and Orion. CK served on advisory boards for Acceleron, Akcea, Alexion, Alnylam, Argenx, Biogen, CSL Behring, Cytokinetics, and Sanofi Genzyme. MCK receives funding from National Health & Medical Research Council of Australia. SJK served as a consultant for AveXis, Biogen, and Roche and receives grant support from AveXis. GM has research contracts with Cytokinetics, Mallinckrodt, Orion, and University of Calgary; and received fees for speaking, advisory board, and travel from Mitsubishi Tanabe Pharma Canada. MN received honoraria from Biogen, Novartis, and Sanofi for chairing and speaking at professional development meetings. BO serves as a consultant for Biogen, Biohaven, MediciNova, Mitsubishi, and Tsumura; and receives research funding from Biogen, Eisai, Genentech, Mitsubishi, and Orion. EPP received clinical trial and research funding from ALS Association, Iron Horse Diagnostics, and NIH/CDC, and served as consultant to Avanir Pharmaceuticals, Biohaven Pharmaceuticals, Cytokinetics, ITF Pharma, Mitsubishi Tanabe Pharma America, and Otsuka America. MP received honoraria from Argenx, Bioproducts Laboratory, CSL Behring, Catalyst, Grifols, and Stealth BioTherapeutics. DQ received research funding from Alnylam, Argenx, Cytokinetics, Flex Pharma, and Momenta. ZS is a consultant for Biogen and Cytokinetics, and received research support from Biogen. JS received grant funding from FSHD Society, Friends of FSH Research, MDA, and NINDS; is a consultant or on advisory boards for Acceleron, Dyne, FACIO, Fulcrum, Genzyme, Mitsubishi Tanabe Pharma, and Sarepta. AS received research support from Amylyx. LHV serves on scientific advisory boards for Biogen, Cytokinetics, and Orion; received an educational grant from Takeda; serves on the editorial boards of Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration and the Journal of Neurology, Neurosurgery, and Psychiatry; and receives research support from the Netherlands ALS Foundation, and The Netherlands Organization for Health Research and Development (Vici Scheme, JPND [SOPHIA, STRENGTH, ALSCare]). MW received funding from ALSA Association and ALS Finding a Cure; is a speaker for NuFactor; and is a consultant for Argenx and Ra Pharma. JW received research funding from Cytokinetics as part of the study. LZ received honoraria from Biogen, Cytokinetics, and Mitsubishi Tanabe Pharma. BMC owns stock in and was an employee of Cytokinetics during the conduct of the study. LM, JW, AAW, FIM, and SAR own stock and are employees of Cytokinetics. JC, AD, SAG, NAG, DH, LK, SL, JSM, GLP, KR, KLS, DS, CS, SS, TV, SV, and AW-R report no relevant disclosures.

Figures

**Figure 1.**
Patient disposition. *All patients randomized contributed to the primary and secondary efficacy analyses, except for 1 patient who withdrew consent right after randomization and did not receive any treatment in the placebo group; all dosed patients contributed to the safety analysis. ^†2 patients were off study drug too long due to prolonged hospitalization. ^‡1 patient no longer wanted to participate in the study due to factors other than the study treatment or study procedures, 1 patient had difficulty traveling to clinic visits, 1 patient withdrew for personal reasons. ^§1 patient could not continue the study and required visits due to unforeseen work events, 1 patient withdrew due to family circumstances. ^¶2 patients did not feel were benefiting from treatment and decided to discontinue, 1 patient had difficulty traveling to clinic visits. AE: adverse event; bid: twice daily; ET: early termination.

**Figure 2.**
LS mean change from baseline for each group from a mixed model analysis of (A) percent predicted SVC (primary endpoint), (C) ALSFRS-R total score, and (E) muscle strength mega-score. Post hoc analysis of LS mean change from baseline from a mixed model analysis for all *reldesemtiv*-treated patients versus placebo for (B) percent predicted SVC, (D) ALSFRS-R Total Score, and (F) muscle strength mega-score. ALSFRS-R: Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised; bid, twice daily; BL: baseline; LS: least squares; SE: standard error; SVC: slow vital capacity; wk: week.

**Figure 3.**
Forest plots from post hoc analyses of LS mean differences between treatment with *reldesemtiv* and placebo by subgroups for (A) percent predicted SVC, (B) ALSFRS-R, and (C) muscle strength mega-score. *Pretrial reduction of ALSFRS-R total score per month. ALSFRS-R: Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised; CI: confidence interval; LSM: least squares mean; pbo: placebo SVC: slow vital capacity.

**Figure 4.**
Post hoc analysis of change from baseline in (A) ALSFRS-R Total Score, (B) ALSFRS-R Fine Motor Domain and (C) ALSFRS-R Gross Motor Domain score by progressor tertiles. ALSFRS-R: Amyotrophic Lateral Sclerosis Functional Rating Scale Revised; FP: fastest progressors; LS: least squares; MP: middle progressors; SP: slowest progressors.

**Figure 5.**
eGFR (based on cystatin C) over time. bid: twice daily; BL: baseline; eGFR: estimated glomerular filtration rate; LS: least squares; wk: week.

See this image and copyright information in PMC

References

1. Shefner J, Cedarbaum JM, Cudkowicz ME, Maragakis N, Lee J, Jones D, et al. Safety, tolerability and pharmacodynamics of a skeletal muscle activator in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2012;13:430–8. - PubMed
1. Shefner JM, Watson ML, Meng L, Wolff AA. A study to evaluate safety and tolerability of repeated doses of tirasemtiv in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2013; 14:574–81. - PubMed
1. Shefner JM, Wolff AA, Meng L. The relationship between tirasemtiv serum concentration and functional outcomes in patients with ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:582–5. - PubMed
1. Sanders DB, Rosenfeld J, Dimachkie MM, Meng L, Malik FI. A double-blinded, randomized, placebo-controlled trial to evaluate efficacy, safety, and tolerability of single doses of tirasemtiv in patients with acetylcholine receptor-binding antibody-positive myasthenia gravis. Neurotherapeutics. 2015;12:455–60. - PMC - PubMed
1. Shefner JM, Wolff AA, Meng L, Bian A, Lee J, Barragan D, et al. A randomized, placebo-controlled, double-blind phase IIb trial evaluating the safety and efficacy of tirasemtiv in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2016; 17:426–35. - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

Associated data

Actions
- Search in PubMed
- Search in ClinicalTrials.gov

Grants and funding

UL1 TR001420/TR/NCATS NIH HHS/United States

LinkOut - more resources

Full Text Sources
Medical
- ClinicalTrials.gov
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS

Affiliations

A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

References

Publication types

MeSH terms

Associated data

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous